The Prophylactic Effect of Stilamin on Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis
Status:
Unknown status
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
Pancreatitis are one of the most common complications of post-ERCP (Endoscopic Retrograde
Cholangiopancreatography), the incidence rate is 5&-10%, how to prevent PEP and
hyperamylasemia is an important issue, somatostatin is widely used in the field of pancreas
treatment. In order to explore the effects of somatostatin on prevent PEP(post-ERCP
Pancreatitis), 908 subjects will be enrolled in two group in the study, one group is given
common treatment, the other uses somatostatin in the base of common treatment.